Abstract 63P
Background
One important limitation of the current standard approach of mobilizing hematopoietic stem cells (HSCs) in the peripheral blood (PB) using granulocyte-colony stimulating factor (G-CSF) for the prophylaxis of chemotherapy induced febrile neutropenia or in donors for PB stem cell transplantation (PBSCT) is insufficient mobilization. Based on our preliminary results on the effect of human chorionic gonadotropin (HCG) on stimulating the peripheral mobilization of HSCs in vivo, the aim of the current study was to assess the effect of the addition of HCG to mobilization with G-CSF on the overall survival (OS) as the primary endpoint in a mouse model of PBSCT.
Methods
Male donor mice (n=20) were pretreated with a single dose of either peg-G-CSF alone (group A, n=10) or HCG + peg-G-CSF (group B, n=10), 5 days prior to PBMC harvest. PBMCs were immediately transplanted to the equivalent number of Busulfan mieloablated female mice by intravenous tail injection and OS was assessed in both recipient groups.
Results
The median OS in the group of recipients transplanted with peg-G-CSF mobilized PBMCs (group A`) was 81 days. In the recipients transplanted with HCG+ peg-G-CSF mobilized PBMCs (group B`} the median OS is not reached at 154 days with 90% of the recipients still being alive.
Conclusions
Addition of HCG to the current standard mobilization approach with G-CSF in donors has almost doubled the survival rate in the recipients of a murine model of PBSCT with the median OS not yet reached after 154 days. This prompts for the translation of the preclinical study`s approach in a human proof-of-principle/feasibility clinical trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Executive Agency for Higher Education, Research and Innovation Funding (UEFISCDI), Ministry of National Education (MEN), Romania.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
80P - Steroidal oximes: A new potential therapeutic approach for cancer treatment
Presenter: Mafalda Laranjo
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
83P - Impact of VHL-associated tumor treatment on mental health: An international patient survey
Presenter: Othon Iliopoulos
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09
88P - PPM1D/WIP1 phosphatase mediates basal and genotoxic stress-induced autophagy via ULK-1 de-phosphorylation
Presenter: Ceylan Ak
Session: Poster session 09